A comparative study of Depo-Provera® versus Norethisterone acetate in management of endometrial hyperplasia without atypia | ||||
| The Egyptian Journal of Fertility of Sterility | ||||
| Article 2, Volume 19, Issue 2 - Serial Number 11106352, June 2015, Page 8-15 PDF (2.5 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/egyfs.2015.257679 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| Ahmed Mohamed NOOH, Hussein Mohammed ABDELDAYEM1, 2 | ||||
| 1Consultant (Assistant Professor) Obstetrics and Gynecology Department, Zagazig University Students’ Hospital, Zagazig, Egypt | ||||
| 2Obstetrics and Gynecology Department, Zagazig University Faculty of Medicine, Zagazig, Egypt | ||||
| Abstract | ||||
| Background: The objective of this study was to assess effectiveness and safety of Depo-Provera® (Medroxyprogesterone acetate - MPA) in treatment of endometrial hyperplasia (EH), and to compare it with Norethisterone acetate (NETA) as an oral progestogen treatment. Methods: This was a prospective randomized trial where 146 women aged 35-50 years with abnormal uterine bleeding who were diagnosed as having EH were randomized to receive either Depo-Provera; one injection every 3 months (2 doses), or oral cyclic NETA; 15 mg daily for 14 days per cycle for 6 months. Primary outcome measure was regression of EH which was analyzed by intention to treat. Secondary outcome variables were side effects of treatment, persistence/progression of EH during follow-up period. Results: After 6 months treatment, Depo-Provera was more successful in achieving regression of non-atypical EH than NETA [67 out of 73 women (91.8%) vs. 49 out of 73 (67.1%), respectively], and the difference between the two groups was statistically significant (RR: 1.37; 95% CI: 1.15-1.63, p = 0.048*). Adverse effects were relatively common with moderate differences between the two groups. Conclusions: This study showed that Depo-Provera is an effective and safe treatment for EH without atypia. Given its availability, apparent safety, and relatively reduced cost, Depo-Provera® deserves to be considered in further larger-sized, multi-centre, double blind, randomized, placebo-controlled trials prior to recommending it for routine use in women with EH. | ||||
| Keywords | ||||
| Keywords: Depo-Provera; Medroxyprogesterone acetate; Norethisterone acetate; endometrial hyperplasia | ||||
|
Statistics Article View: 98 PDF Download: 46 |
||||
